Skip to main navigation Skip to search Skip to main content

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

  • University of Bristol
  • North Bristol NHS Trust
  • University Hospitals Bristol and Weston NHS Foundation Trust
  • Saint Göran Hospital
  • Karolinska Institutet
  • University of Oxford
  • Klinik Hirslanden
  • University of Lucerne
  • Medical University of Vienna
  • Aichi Cancer Center Hospital and Research Institute
  • Sheba Medical Center at Tel Hashomer
  • Seoul National University
  • University of Antwerp
  • Athens Medical Center
  • Johns Hopkins University
  • Baylor College of Medicine
  • The University of Sydney
  • University of North Carolina at Chapel Hill
  • University of Newcastle
  • Queen's University Belfast
  • University of Kragujevac
  • University Medical Center of Tirana "Mother Teresa"
  • Silesian University in Opava
  • University of Cyprus
  • Peter Maccallum Cancer Centre
  • University of Sheffield
  • McGill University
  • University of Gothenburg
  • Stanford University
  • Tata Memorial Hospital
  • Aga Khan University
  • Hospital Clinic ICU
  • East Suffolk and North Essex NHS Foundation Trust
  • Manipal Academy of Higher Education

Research output: Contribution to journalJournal articlepeer-review

Abstract

Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.

Original languageEnglish
Article number116
Journalnpj Breast Cancer
Volume11
Issue number1
DOIs
StatePublished - 2025.12

Fingerprint

Dive into the research topics of 'A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials'. Together they form a unique fingerprint.

Cite this